Hiroshi Deguchi

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6090530/publications.pdf

Version: 2024-02-01

713013 932766 32 461 10 21 citations h-index g-index papers 32 32 32 703 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Skeletal muscle myosin promotes coagulation by binding factor XI via its A3 domain and enhancing thrombin-induced factor XI activation. Journal of Biological Chemistry, 2022, 298, 101567.	1.6	6
2	Fullâ€length plasma skeletal muscle myosin isoform deficiency is associated with coagulopathy in acutely injured patients. Journal of Thrombosis and Haemostasis, 2022, 20, 1385-1389.	1.9	3
3	Novel blood coagulation molecules: Skeletal muscle myosin and cardiac myosin. Journal of Thrombosis and Haemostasis, 2021, 19, 7-19.	1.9	7
4	Skeletal muscle myosin and cardiac myosin attenuate heparin's antithrombinâ€dependent anticoagulant activity. Journal of Thrombosis and Haemostasis, 2021, 19, 470-477.	1.9	1
5	Procoagulant activities of skeletal muscle and cardiac myosins require both myosin protein and myosin-associated anionic phospholipids. Blood, 2021, 137, 1839-1842.	0.6	2
6	Skeletal Muscle Myosin Is Procoagulant By Binding Factor XI Via Its A3 Domain and Enhancing Factor XI Activation By Thrombin. Blood, 2021, 138, 441-441.	0.6	0
7	Activated protein C anticoagulant activity is enhanced by skeletal muscle myosin. Haematologica, 2020, 105, e424-e427.	1.7	5
8	Cardiac Myosin Promotes Thrombin Generation and Coagulation In Vitro and In Vivo. Arteriosclerosis, Thrombosis, and Vascular Biology, 2020, 40, 901-913.	1.1	7
9	Plasma skeletal muscle myosin phenotypes identified by immunoblotting are associated with pulmonary embolism occurrence in young adults. Thrombosis Research, 2020, 189, 88-92.	0.8	4
10	Novel exomic rare variants associated with venous thrombosis. British Journal of Haematology, 2020, 190, 783-786.	1.2	13
11	Striated muscle myosin and blood coagulation. Japanese Journal of Thrombosis and Hemostasis, 2020, 31, 394-397.	0.1	0
12	Molecular interaction site on procoagulant myosin for factor Xa–dependent prothrombin activation. Journal of Biological Chemistry, 2019, 294, 15176-15181.	1.6	10
13	Cardiac and Skeletal Muscle Myosin Exert Procoagulant Effects. Shock, 2019, 52, 554-555.	1.0	11
14	Low level of the plasma sphingolipid, glucosylceramide, is associated with thrombotic diseases. Research and Practice in Thrombosis and Haemostasis, 2017, 1, 33-40.	1.0	7
15	Minor plasma lipids modulate clotting factor activities and may affect thrombosis risk. Research and Practice in Thrombosis and Haemostasis, 2017, 1, 93-102.	1.0	14
16	Elevated CETP Lipid Transfer Activity is Associated with the Risk of Venous Thromboembolism. Journal of Atherosclerosis and Thrombosis, 2016, 23, 1159-1167.	0.9	13
17	Prothrombotic skeletal muscle myosin directly enhances prothrombin activation by binding factors Xa and Va. Blood, 2016, 128, 1870-1878.	0.6	34
18	Arteriovenous Blood Metabolomics: A Readout of Intra-Tissue Metabostasis. Scientific Reports, 2015, 5, 12757.	1.6	62

#	Article	IF	CITATIONS
19	Inhibition of thrombin generation in human plasma by phospholipid transfer protein. Thrombosis Journal, 2015, 13, 24.	0.9	6
20	Lyso-Sulfatide Binds Factor Xa and Inhibits Thrombin Generation by the Prothrombinase Complex. PLoS ONE, 2015, 10, e0135025.	1.1	4
21	Re-Evaluation of the Anticoagulant Properties of High-Density Lipoprotein—Brief Report. Arteriosclerosis, Thrombosis, and Vascular Biology, 2015, 35, 570-572.	1.1	11
22	Warfarin untargeted metabolomics study identifies novel procoagulant ethanolamide plasma lipids. British Journal of Haematology, 2014, 165, 409-412.	1.2	8
23	Plasma High Density Lipoprotein and Anticoagulant Response to Activated Protein C (APC) and Protein S. Blood, 2011, 118, 2249-2249.	0.6	1
24	Warfarin Untargeted Metabolomics Study Identifies Novel Procoagulant Ethanolamide Lipids. Blood, 2011, 118, 1200-1200.	0.6	1
25	Plasma Serum Amyloid A Levels Are Increased In Venous Thrombosis Patients and Are Correlated with Blood Coagulability. Blood, 2010, 116, 155-155.	0.6	1
26	Activation of the PI3K-Akt Pathway by Activated Protein C Occurs Via a Novel Receptor, Apolipoprotein E Receptor 2 (ApoER2). Blood, 2008, 112, 695-695.	0.6	0
27	Plasma cholesteryl ester transfer protein and blood coagulability. Thrombosis and Haemostasis, 2007, 98, 1160-4.	1.8	5
28	Risk of Recurrent Venous Thromboembolism Reduced by High Density Lipoproteins Blood, 2006, 108, 271-271.	0.6	4
29	High-Density Lipoprotein Deficiency and Dyslipoproteinemia Associated With Venous Thrombosis in Men. Circulation, 2005, 112, 893-899.	1.6	156
30	Sphingolipids as Bioactive Regulators of Thrombin Generation. Journal of Biological Chemistry, 2004, 279, 12036-12042.	1.6	46
31	Neutral Glycosphingolipid-dependent Inactivation of Coagulation Factor Va by Activated Protein C and Protein S. Journal of Biological Chemistry, 2002, 277, 8861-8865.	1.6	19
32	ç³–è,,,質ã•å‡å,º. Japanese Journal of Thrombosis and Hemostasis, 2002, 13, 2-8.	0.1	0